Clinical Trial Detail

NCT ID NCT03425461
Title Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

melanoma

Therapies

Ipilimumab + Pepinemab

Nivolumab + Pepinemab

Age Groups: senior adult

No variant requirements are available.